To call this a research report is a long stretch. More like an ignorant attempt to apply financial and market ratios to a biotech company where unfortunately you just have to throw some fundamental ratios out the window otherwise you simply would not go there, in which you would not have a biotech industry period without investors.
But I digress. This was a released on 19th July and would done us no favours. Especially the part about price to book value comparison.
http://www.buysellsignals.com/1021150
Fluxmaker
research report
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
